TY - JOUR
T1 - The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice
AU - Clinchy, Birgitta
AU - Vitetta, Ellen S.
N1 - Funding Information:
The authors wish to thank Ms. Lien Le for expert technical assistance and Ms. Shannon Flowers for preparation of the manuscript. This work was supported in part by NIH grant CA-28149 and a fellowship from the Swedish Cancer Society. Investigators interested in the 64.1-dgA IT should contact the corresponding author.
PY - 1998/9/1
Y1 - 1998/9/1
N2 - Severe combined immunodeficient mice (SCID) reconstituted with normal PBLs (SCID/PBL) from Epstein-Barr virus-positive (EBV+) human donors often develop fatal human B lymphomas which resemble the EBV-induced lymphoproliferative disease (LPD) observed in immunosuppressed individuals. This phenomenon appears to be T cell dependent. In this study we used an immunotoxin (IT) prepared by conjugating the monoclonal anti-CD3 antibody, 64.1, to deglycosylated ricin A chain (dgRTA) to prevent LPD in SCID/PBL mice. We show that the incidence of LPD is greatly reduced by either a combination of in vitro treatment of PBLs followed by one in vivo treatment of the xenografted mice with 64.1-dgRTA immunotoxin or by repeated treatments in vivo with the immunotoxin. In contrast, in vitro treatment alone or in vivo treatment with only one injection of 64.1-dgRTA were less effective. As expected, this IT did not have any non-specific cytotoxic effects on already established EBV+ tumors from SCID/PBL mice. The use of this IT, therefore, represents a simple method to avoid LPD when injecting blood-containing tissues into SCID mice.
AB - Severe combined immunodeficient mice (SCID) reconstituted with normal PBLs (SCID/PBL) from Epstein-Barr virus-positive (EBV+) human donors often develop fatal human B lymphomas which resemble the EBV-induced lymphoproliferative disease (LPD) observed in immunosuppressed individuals. This phenomenon appears to be T cell dependent. In this study we used an immunotoxin (IT) prepared by conjugating the monoclonal anti-CD3 antibody, 64.1, to deglycosylated ricin A chain (dgRTA) to prevent LPD in SCID/PBL mice. We show that the incidence of LPD is greatly reduced by either a combination of in vitro treatment of PBLs followed by one in vivo treatment of the xenografted mice with 64.1-dgRTA immunotoxin or by repeated treatments in vivo with the immunotoxin. In contrast, in vitro treatment alone or in vivo treatment with only one injection of 64.1-dgRTA were less effective. As expected, this IT did not have any non-specific cytotoxic effects on already established EBV+ tumors from SCID/PBL mice. The use of this IT, therefore, represents a simple method to avoid LPD when injecting blood-containing tissues into SCID mice.
KW - CD3
KW - Immunotoxin
KW - Lymphoproliferative disease
KW - SCID/PBL
UR - http://www.scopus.com/inward/record.url?scp=0032170351&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032170351&partnerID=8YFLogxK
U2 - 10.1016/S0022-1759(98)00123-9
DO - 10.1016/S0022-1759(98)00123-9
M3 - Article
C2 - 9819131
AN - SCOPUS:0032170351
SN - 0022-1759
VL - 218
SP - 141
EP - 153
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
IS - 1-2
ER -